Thus, a fraction of patients with initial isoniazid resistance will fail on treatment despite the companion drug thioacetazone.  By definition, at the point of failure, such patients will have acquired thioacetazone resistance.  A rifampicin throughout regimen as recommended by The Union and WHO will cure such patients as at all times there are at least two drugs present to which the organisms remain susceptible.

To top